
Teva Pharmaceutical Industries Limited
NYSE•TEVA
CEO: Mr. Richard D. Francis
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 1982-02-16
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Contact Information
Market Cap
$37.60B
P/E (TTM)
-240.8
93.6
Dividend Yield
--
52W High
$33.42
52W Low
$12.47
52W Range
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$4.48B+3.42%
4-Quarter Trend
EPS
$0.38-197.44%
4-Quarter Trend
FCF
$233.00M-57.25%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Net Income Reverses Loss Net income attributable to Teva $433M in Q3 2025, reversing prior period net loss of $(437)M.
US Profit Jumps 25% US segment profit $937M, up 25% versus Q3 2024, driven by AUSTEDO revenue growth.
Gross Margin Expansion Q3 Gross profit margin improved to 51.4% from 49.6% last year, reflecting favorable product mix.
Operating Income Swing Operating income $882M in Q3 2025, a major swing from $51M operating loss in Q3 2024.
Risk Factors
Ongoing Legal Contingencies Provision for legal settlements $60M in Q3 2025; opioid/antitrust litigation remains material exposure.
API Divestiture Uncertainty Strategic intention to divest API business continues, but ultimate timing or completion is not assured.
Significant Debt Load Significant indebtedness may limit ability to incur additional debt or make new strategic investments.
Currency Fluctuation Impact Approximately 41% of Q3 revenues denominated in non-USD currencies, creating foreign exchange risk exposure.
Outlook
Accelerate Growth Strategy Executing second phase of Pivot to Growth strategy, focusing capital allocation on high-value innovative portfolio.
Workforce Transformation Plan Transformation programs announced May 2025 target 8% workforce reduction by end of 2027 for cost savings.
Innovative Pipeline Advancement DARI (ICS/SABA) and duvakitug (anti-TL1A) both advanced to Phase 3 clinical trials.
Liquidity Position Strong Expects sufficient cash resources to support all debt service payments and financial obligations within one year.
Peer Comparison
Revenue (TTM)
GMAB$18.26B
TEVA$16.78B
LH$13.77B
Gross Margin (Latest Quarter)
NBIX98.2%
GMAB94.3%
BNTX90.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TEVA | $37.60B | -240.8 | -2.6% | 42.9% |
| NTRA | $32.50B | -104.5 | -25.1% | 10.1% |
| BIIB | $27.23B | 16.9 | 9.3% | 22.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.9%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Jan 28, 2026
EPS:$0.64
|Revenue:$4.33B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 5, 2025|Revenue: $4.48B+3.4%|EPS: $0.38-197.4%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 30, 2025|Revenue: $4.18B+0.3%|EPS: $0.25-133.3%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 7, 2025|Revenue: $3.89B+1.5%|EPS: $0.19-258.3%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 5, 2025|Revenue: $16.54B+4.4%|EPS: $-1.45-190.0%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 6, 2024|Revenue: $4.33B+12.5%|EPS: $-0.39-646.2%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 31, 2024|Revenue: $4.16B+7.3%|EPS: $-0.75-2.6%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $3.83B+4.6%|EPS: $-0.12-40.0%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 12, 2024|Revenue: $15.85B+6.2%|EPS: $-0.50+77.3%Miss